

Invitation to Submit New Study Proposal

Exploring Novel Investigational Approaches in Multiple Myeloma (MM) Phase II/III Trials in Relapsed/Refractory Multiple Myeloma (1L and 2L Relapse)

Background

Plasma cell malignancies, including multiple myeloma (MM), amyloidosis and plasma cell leukemia, remain challenging and heterogeneous diseases, despite significant advancements in treatment. The European Myeloma Network (EMN), an academic non-profit organization, was established to advance understanding of these plasma cell malignancies, and to produce high-quality research initiatives and clinical trials.

Academic studies play a crucial role in addressing unmet clinical needs, advancing our understanding of disease biology (incl. mechanisms of resistance and role of biomarkers) and often focus on underrepresented populations, such as elderly, frail or high-risk patients, ensuring impact on the real-world clinical setting. Academic research drives innovation and is essential to improve patient outcomes and optimize treatment strategies (incl optimal treatment sequencing, combinations of existing therapies, and strategies for dose or duration adjustment) across the MM continuum.

At the same time, patients experiencing their first or second relapse continue to face considerable clinical challenges. Optimizing treatment sequencing and evaluating novel combinations or mechanisms of action in the **relapse** setting is essential to improving long-term outcomes and potentially altering disease trajectory.

Call for Study Proposals

The Young EMN carefully reviewed the EMN study pipeline and the available trials for myeloma patients and concluded that it would be most beneficial to focus efforts on two specific areas (listed below). Therefore, as a nonprofit academic research organization, and on behalf of the Young EMN Board, we invite the submission of

1. New study proposals for academic studies focusing on innovative approaches in MM, including but not limited to:

- Early-phase (II) clinical trials with specific biological or clinical question
- Combinations of emerging therapies or sequencing strategies or mode-of action studies
- Translational and biomarker-driven research
- Mechanisms of resistance and disease progression
- Minimal residual disease (MRD) and novel endpoints

2. Proof of Concept Phase II trials aimed at addressing the critical unmet needs in relapsed/refractory multiple myeloma (RRMM), particularly in first and second relapse (post FL triple or quadruplet regimens, post FL novel immunotherapies, following Len and/or PI refractory disease). Focus areas of interest include (but are not limited to):

- Novel drug combinations or sequencing strategies
- Follow up studies to existing frontline EMN studies (e.g. EMN17/Perseus study, EMN28, EMN30)
- Immunotherapies and T-cell redirection approaches
- Strategies tailored to molecular subgroups or high-risk disease

Scope

Proposals should address an unmet need or critical gap in the current MM, amyloidosis or PCL landscape. Both interventional studies/clinical trials and translational/correlative studies, including both academic and industry-partnered projects, will be considered.

Eligibility

Academic investigators or national groups with proven experience. Preference will be given to proposals that enhance collaboration among investigators and studies that build on existing (EMN) studies.

Proposal Format and Submission

Please submit a brief concept (1-2 pages), including:

- Study rationale and objectives
- Proposed methodology
- Target patient population and setting
- Estimated timeline

If available:

- In case of clinical trial: proposed design (randomization, endpoints, sample size), comparator arm & justification and key feasibility considerations.
- Funding plan (including local and national funding grants and specification of total budget estimate)
- Required support from EMN, e.g. logistics, management support, funding, drug supply, regulatory guidance etc.

Deadline for Initial Submission: 15 January 2026. Thereafter, proposals may be submitted during four annual rounds.

Submit proposals to: Giorgio Schirripa (giorgio.schirripa@emn.org), CC Young EMN Board President (Dr. Broijl (a.broyl@erasmusmc.nl))

All study proposals will be treated as confidential. A confidentiality agreement can be signed with EMN upon request.

For questions or to schedule a preliminary discussion, please contact: Giorgio Schirripa (giorgio.schirripa@emn.org)

Prof. P. Sonneveld, EMN President

Prof. M. Boccadoro, EMN Vice-President

.